Meet the Executive Leadership Team
![](https://www.demerx.com/wp-content/uploads/2022/08/dr-deborah-mash-1.jpg)
Deborah C. Mash PhD, Director,
Chief Executive Officer and President
![ME Profile Picture ME Profile Picture](https://www.demerx.com/wp-content/uploads/2024/07/ME-Profile-Picture.jpg)
Mark Ellison, PhD
President of Clinical Operations and Chief Development Officer
Mark Ellison has over 25 years of pharmaceutical experience with a track record of propelling start-ups & small pharma to maximize their capabilities in moving new products through the development process & bringing them to market. Mark was the Chief Development Officer at Opiant Pharmaceuticals who developed Narcan Nasal Spray a life changing product in the battle against opioid overdose, and Opvee (Nalmefene) Nasal Spray a product with the potential to tackle the fentanyl crisis. Prior to this he served as the Head of Technical Affairs at S.L.A. Pharma and held leadership and management positions at the Medicines and Healthcare Products Regulatory Agency (MHRA), Link Pharmaceuticals, DMV International and Merck.
![](https://www.demerx.com/wp-content/uploads/2024/07/DrKramer.jpg)
E. Douglas Kramer, MD
Vice President, Clinical and Regulatory Affairs
Dr. Kramer obtained his medical degree from Columbia University and has more than 30 years of experience in drug development including regulatory affairs, pharmacovigilance, management, and domestic and international drug control and abuse liability evaluation. He has advanced the clinical development of addiction treatment medicines, opioid and non-opioid analgesics, and cancer chemotherapy in large and small pharmaceutical companies. Dr. Kramer has experience in all phases of development from pre-IND to Phase 3. He was previously a Medical Officer for the FDA Center for Drug Evaluation and Research Division of Anesthetic, Critical Care, and Addiction Drug Products. During his time with the FDA, he reviewed INDs and NDAs for analgesics in development (including NSAID, opioid, and combination products in both immediate-release and controlled-release dosage forms), the treatment of substance use disorders (including nicotine, opioid, stimulant dependence, and alcoholism) and requests for INDs for human administration of drugs of abuse.
![](https://www.demerx.com/wp-content/uploads/2022/08/2-1.jpg)
John C. Thomas Jr., Treasurer
Chief Financial Officer and Secretary
John C. Thomas, Jr. has served as our Treasurer, Chief Financial Officer and Secretary since 2017, he previously held the Chief Financial Officer position at the Company from 2010 – 2013. Mr. Thomas also has served as Chief Financial Officer of the following companies founded by one of DemeRx’s co-founders, Mr. Steve Gorlin: CoRegen, Inc., MiMedx Group, Inc., a publicly-held biotechnology company (2007 – 2008) and SpineMedica, Corp., a subsidiary of MiMedx Group, Inc. (2005 – 2006); DARA BioSciences, Inc., a publicly-held biotechnology company (2002 – 2009), ClearPoint Neuro, a publicly-held company involved in MRI technology (1998 – 2010); GMP Companies, Inc., a private medical research company (1999 – 2001); EntreMed, Inc. a publicly-held biopharmaceutical research and development company (1991 – 1997); Medicis Pharmaceutical Corporation, a publicly-held dermatological company (1988 – 1991); Biopool International, Inc. (formerly CytRx Biopool, Ltd.), a publicly-held company engaged in the sale of pharmaceutical diagnostic test kits (1990 – 1991); and CytRx Corporation, a publicly-held pharmaceutical research and development company (1986 – 1989). Mr. Thomas has also served as the chief financial officer for several other start-up companies in other industries during the past ten years as the Chief Financial Officer including Motion Reality, Inc., a privately-held virtual reality company (2001 – present), and CorMatrix Cardiovascular, Inc., a privately held medical device company (2001 – 2018). Mr. Thomas is a certified public accountant.
![](https://www.demerx.com/wp-content/uploads/2022/08/addinoff-1.jpg)
Bryon Adinoff, MD
Lead Consultant Psychiatry
![](https://www.demerx.com/wp-content/uploads/2022/08/Untitled-1.jpg)
Pascal J. Goldschmidt MD,
Director, Lead Consultant Cardiology
Meet the Board of Directors
![](https://www.demerx.com/wp-content/uploads/2022/08/Untitled6-1.jpg)
Christopher Hassan
![](https://www.demerx.com/wp-content/uploads/2022/08/Untitled2-1.jpg)
Amb. Hans Hertell
![](https://www.demerx.com/wp-content/uploads/2022/08/Untitled5-1.jpg)
Heather Callander-Potters, MBA
![](https://www.demerx.com/wp-content/uploads/2022/08/guy-bolton-1.jpg)